Date of Award
Spring 2025
Document Type
Thesis
Submission Date
May 2025
Degree Name
Professional Science Masters (PSM)
Department
Physics
Abstract
The primary objective of this study was to evaluate the patient-specific quality assurance (PSQA) performance for various disease sites treated with the Radixact machine using Gamma (γ) passing rate analysis (%GP) as per AAPM TG-218.
This study analyzed 22 PSQA plans executed on a Radixact machine using ArcCheck phantom and delivery analysis (DA) software. The %GP was calculated using a 3% dose difference (DD), a 2 mm distance-to-agreement (DTA), and a 10% threshold. A passing criterion of ≥95% was applied for PSQA evaluation.
The %GP was analyzed for all sites. The %GP (2D) on the ArcCheck phantom mean γ passing rate with variability was (97.12±2.63%), while the %GP (3D) rate for DA was 100%.
For DA, the %GP was 100% because it only considers the MLC-LOTs patterns, not plan parameters, to compute the delivered versus planned dose. Investigations should be required to recalibrate the output of the MVCT diode array.
Thesis/Dissertation Advisor [Chair]
Silvia Pella,
Thesis/Dissertation Co-Chair
Theodora Leventouri
Recommended Citation
Pama, Gagandeep, "CLINICAL VALIDATION OF DELIVERY ANALYSIS SOFTWARE FOR PATIENT-SPECIFIC QUALITY ASSURANCE OF RADIXACT (TOMOTHERAPY) TREATMENT" (2025). Electronic Theses and Dissertations. 44.
https://digitalcommons.fau.edu/etd_general/44